Literature DB >> 30357262

The Next Stage of Buprenorphine Care for Opioid Use Disorder.

Stephen A Martin1, Lisa M Chiodo2, Jordon D Bosse2, Amanda Wilson3.   

Abstract

Buprenorphine has been used internationally for the treatment of opioid use disorder (OUD) since the 1990s and has been available in the United States for more than a decade. Initial practice recommendations were intentionally conservative, were based on expert opinion, and were influenced by methadone regulations. Since 2003, the American crisis of OUD has dramatically worsened, and much related empirical research has been undertaken. The findings in several important areas conflict with initial clinical practice that is still prevalent. This article reviews research findings in the following 7 areas: location of buprenorphine induction, combining buprenorphine with a benzodiazepine, relapse during buprenorphine treatment, requirements for counseling, uses of drug testing, use of other substances during buprenorphine treatment, and duration of buprenorphine treatment. For each area, evidence for needed updates and modifications in practice is provided. These modifications will facilitate more successful, evidence-based treatment and care for patients with OUD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30357262     DOI: 10.7326/M18-1652

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  27 in total

1.  Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder.

Authors:  Elizabeth E Krans; Joo Yeon Kim; Alton Everette James; David Kelley; Marian P Jarlenski
Journal:  Obstet Gynecol       Date:  2019-05       Impact factor: 7.661

2.  ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.

Authors:  Ryan Marino; Jeanmarie Perrone; Lewis S Nelson; Timothy J Wiegand; Evan S Schwarz; Paul M Wax; Andrew I Stolbach
Journal:  J Med Toxicol       Date:  2019-08-14

3.  ACMT Position Statement: Buprenorphine Administration in the Emergency Department.

Authors:  Paul M Wax; Andrew I Stolbach; Evan S Schwarz; Brandon J Warrick; Timothy J Wiegand; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2019-05-13

4.  Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid.

Authors:  Hillary Samples; Arthur Robin Williams; Stephen Crystal; Mark Olfson
Journal:  Health Aff (Millwood)       Date:  2020-05       Impact factor: 6.301

5.  Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study.

Authors:  Tamara Beetham; Brendan Saloner; Sarah E Wakeman; Marema Gaye; Michael L Barnett
Journal:  Ann Intern Med       Date:  2019-06-04       Impact factor: 25.391

6.  A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients.

Authors:  Hsien-Yen Chang; Noa Krawczyk; Kristin E Schneider; Lindsey Ferris; Matthew Eisenberg; Tom M Richards; B Casey Lyons; Kate Jackson; Jonathan P Weiner; Brendan Saloner
Journal:  Drug Alcohol Depend       Date:  2019-06-07       Impact factor: 4.492

7.  Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.

Authors:  Andrea Jakubowski; Tiffany Lu; Frank DiRenno; Benjamin Jadow; Angela Giovanniello; Shadi Nahvi; Chinazo Cunningham; Aaron Fox
Journal:  J Subst Abuse Treat       Date:  2020-09-22

8.  Implementing group visits for opioid use disorder: A case series.

Authors:  Randi Sokol; Mark Albanese; Chiara Albanese; Gerard Coste; Ellie Grossman; Diana Morrill; David Roll; Amy Sobieszczyk; Zev Schuman-Olivier
Journal:  Subst Abus       Date:  2019-08-16       Impact factor: 3.716

9.  How Clinicians Caring for Youth Can Address the Opioid-Related Overdose Crisis.

Authors:  Scott E Hadland
Journal:  J Adolesc Health       Date:  2019-08       Impact factor: 5.012

10.  Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality.

Authors:  Alex K Gertner; Allison G Robertson; Byron J Powell; Hendree Jones; Pam Silberman; Marisa Elena Domino
Journal:  Health Aff (Millwood)       Date:  2020-08       Impact factor: 6.301

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.